Treatment of urinary incontinence and related disorders, by increasing intracellular cyclic adenosine monophosphate concentration, e.g. using adenyl cyclase stimulant such as forskolin

摘要

Use of intracellular cyclic adenosine monophosphate (cAMP) concentration increasing agents (I) for treating urge symptoms, urge incontinence, pollakiuria, nycturia and detrusor muscle instability, where (I) is a cellular adenyl cyclase stimulant, modulator of binding to beta 1-, beta 2- or beta 3-adrenoceptors of the urinary bladder musculature or a cellular cAMP hydrolyzing phosphodiesterase inhibitor. The use of intracellular cyclic adenosine monophosphate (cAMP) concentration increasing agents (I) is claimed for treating urge symptoms, urge incontinence, pollakiuria, nycturia and detrusor muscle instability, where (I) is selected from (a) cellular adenyl cyclase stimulants, (b) modulators of binding to beta 1-, beta 2- or beta 3-adrenoceptors of the urinary bladder musculature and (c) cellular cAMP hydrolyzing phosphodiesterase inhibitors. Alternatively (I) is replaced by cAMP analogs (II) which stimulate the phosphorylating activity of cellular cAMP-binding protein kinases and thus reduce the cytosolic calcium ion concentration. An Independent claim is included for pharmaceutical preparations comprising combinations of (I) (a)-(c).